Identifying and validating new kinase targets to develop a rational therapy for invasive lobular carcinoma and triple negative breast cancer

Invasive lobular carcinoma accounts for 10 percent of breast cancer worldwide, and triple negative breast cancer for 15 percent. The EU-funded RATHER (”Rational therapy for breast cancer: individualised treatment for difficult-to-treat breast cancer subtypes”) project is determined to identify and validate new kinase targets to treat both subtypes. Read more here.

Connect to the Rather project website here.